Competitive Intelligence

and Analytics

© 2015 Indegene. All rights reserved.

About Indegene

Next-generation solutions enabling global healthcare

organizations to improve health and business outcomes.

LIFESCIENCES PAYERS PROVIDERS

2
Customers

3
Solutions for the Healthcare Stakeholders
Comprehensive solutions for Life Sciences , Payers & Providers to improve health outcomes,
increase revenue, optimize costs, and engage customers better.

LIFESCIENCES PAYERS PROVIDERS

Medical Marketing Risk and Quality Clinical Population Health

Solutions Solutions Solutions Effectiveness Management
Labelling MCM | Digital factory Quality Improvement - Provider and Member Population Analytics |
| Regulatory and Safety STARS / QRS / HEDIS Engagement | Clinical & Care Management |
| Commercial
Writing | Promotional | Risk Adjustment Financial Analytics | Care Patient and Physician
Analytics
Review | HEOR | Operations – MRR , management engagement
| Learning & Coding , Analytics
Development | Pharmacy Support

4
The ATOM Advantage

Proprietary Medical interactions

Suite of platforms to
analytic frameworks to drive
drive effective medical
insights for commercialization
interactions
and better health outcomes

Deep Expertise in medical science

Robust , scalable & secure and network of clinicians across
global operational expertise therapies and countries

5
Next-generation Healthcare Platforms

6
Deep & Diverse Talent
5%
CANADA 15%
24% ANALYTICS
MEDICAL EXPERTISE

72% 14% 18%

INDIA US & EU TECHNOLOGY

43%
9% OPERATIONS
CHINA

55% 45%
MALE FEMALE

7
Best in Class Operations

Delivery and Data Local Client Innovation Quality

Centers Support Hubs Management
• 4 global delivery • Local client servicing • Digital and mobility
centers across US, support centres in LA &
India and China • In 50 countries across Montreal, Canada
• Data centers across US, Europe and Asia ISO 9001, 27001
US , Latin America , • Regulatory and local
India and China market understanding

8
Analyst and Industry Acclaim
IDC MARKETSCAPE
Life Sciences, Sales and Life Sciences, Sales
Marketing, Strategic Consulting and Marketing BPO

Capabilities

Capabilities
Strategies Strategies

9
Research, Analytics and Insights Services
Domain-intensive integrated insights across the pharma value chain

Business Development and Sales and Client

R&D and Regulatory Affairs Medical Affairs Commercial and Marketing
Licensing Engagement

 Channel Mix Optimisation

 Social Media Monitoring and Analytics
 ROI Analysis
 Multichannel Segmentation and Targeting
 Clinical Trial Analysis
 Trial Timeline Analysis and Forecasting
 Clinical Operations Support
 IP and Patent Analysis
 Sales Force Effectiveness  Publication Analysis
 Market Data Analytics
 Performance Dashboards

 Competitor Activity Tracking

 Disease Landscaping
 Pipeline and Portfolio Analysis
 Epidemiology Studies
 Scenario Planning
 Regulatory Support Services
 Market Research
 Patient Journey Assessment
 Analysis of Health Systems
 Pricing Research  Market Sizing
 Payer Research  New Market Estimation
 Sensitivity Studies
 Emerging Market Models
 Pricing Research
CONFIDENTIAL & PROPRIETARY
10
 Competitive Environmental Monitoring
• Track evolution of environmental trends, sequence of events or streams of activities
• Alert the firm to critical trends before competitors recognize them
• Enable faster and timely decision making

CI Areas Mode of Delivery

Therapy Area
Custom Alerts
Regulatory Update
Indegene
News Conference News Newsletters
Monitoring
Services Clinical Trial Updates
Reports
Commercial News

General News Web-based Platform

Analysis/ Analysis/ Analysis/

Key insights Key insights Key insights

Quarterly
Daily Weekly Monthly
Reports

Confidential 11
 Methodology Overview
Sources

Conferences Syndicated Databases News Social Media Blogs Publications

Collation

Client-subscribed/
shared data if any
Reviewing collected information
Intelligence

Checking for reliability of sources for each selected item Checking for redundancy
Human

Selecting relevant information

Repository
Summarising the information and providing insights
Deliverable

Daily/Weekly/Monthly/Quarterly
Newsletters/Reports – An initial baseline report
and subsequent update reports

Confidential 12
Methodology - Execution Process
Human Intelligence – Selection, assessment and critical analysis
1

3
Next, they will link the
Indegene’s team of Based on their domain
context of the same
subject matter experts expertise, they will
with pre-existing
will review the comprehend the
understanding in order
information and asses information and build a
to bring out the specific
the relevance and story around the
implication of the
importance of the same findings of the news
finding

• Indegene experts will create a write up of their viewpoints on

Viewpoints noteworthy stories on a daily or weekly basis. This will contain a
more detailed analysis of the information.

• Additionally, Indegene will select certain significant advances or

Monthly features trends (for e.g. practice changing updates from a conference) and
create a in- depth feature from the same

www.indegene.com
13
CONFIDENTIAL & PROPRIETARY
 News Coverage: Key Sources*
Therapy Area News
• Bioportfolio.com • Fiercebiotech.com • Pharmalive
• Bioworld • First Word Plus • Pharmalot.com
• Bloomberg.com • Forbes • PR News Letter
• Business week • Market Watch • Reuters Health Care
• CNBC • Medical News Today • The Lancet
• Diabetes.org • Medpage Today • Washington Post
• DowJones.com • Medscape • Competitor Company Websites
• Endocrine • NEJM • Other subscribed databases of the clients
• FDA.Gov • Newsrx.com

Clinical Trial News Competitor News Other Sources

• Clinical trials.gov • Competitor companies’ Web sites • Country-specific pharmaceutical, regulatory,
• DYONISUS: Indegene propriety database, an • Company news releases registry sites, articles, etc
automated data monitor that collects and • Company annual and quarterly filings and Client Provided Pipeline database such as:
categories news from 400+ preselected reports • Thomson Pharma
sources in real-time setting • Company presentations and press releases
• Adis Insights
• Analyst reports • Key congresses during the period
• IDDB3
• WHO clinical trial registry
• Company & country-specific clinical trial • Factiva
registries • Datamonitor Reports
• Analyst Reports

* Only indicative, not exhaustive Confidential 14

Multiple Delivery Formats
SharePoint Web Portal

Excel

Confidential 15
Case Studies

Confidential 16
Case Study: Biosimilar Competitive Intelligence Platform
Objective: To develop an online tracking tool that will serve as a one stop shop for information on key developments in the entire biosimilar
space and monitor activity of key biosimilar players on a regular basis.

Solution: A web-based competitive intelligence portal inclusive of:

KEY FACT 1:
Real-time updates of technical, commercial, and regulatory biosimilar developments globally.
Activity monitor of key biosimilar players (watch list) across North America, Europe, Asia, and Latin America.The project has
been operational
Emerging player tracker, Publication tracker for 3 years.
Reporting tool for innovator firms’ defense strategy.
Key news tracker.

Portal Features Expertise

Demonstrated
Competitor Profile Product portfolio
Competitive activity Multi-sourced real-time domain monitoring
Relevant news
report
Key personnel Emerging market tracking
Product launch timeline
Corporate publications Conference presentation tracking
Information retrieval
between particular Company statements
dates Company-, geography-, and molecule- based
intelligence generation
In-built PDF converter
Key event monitoring (conferences)

Client Speak KEY FACT 2:

Over 200 log-in IDs
“Appreciate all your hard work and diligent support all year round.” issued.
 Snapshot of Biosimilar Platform Competitive Intelligence
Platform Home Add Users Contact Us Change Password Logout

Competitor Biosimilar Competitive Activity Global Biosimilar

News Enter search term SEARCH
Tracker Dashboard Monitor Portfolio

Development & Regulatory Activities Commercialization & Lobbying Operations & Manufacturing General News

Shortcuts

Last 7 days Development & Regulatory Activities Operations & Manufacturing

Last 15 days
FDA to review Teva biosimilar of Amgen's Neupogen Date: DRL invests in biosimilar facility Date: Jan 20, 2010
This month
Feb 2, 2010 Dong-A plans to build new plant to raise output Date: Jan
Last month
3SBio Inc. Applies for SFDA Registrational Trial for 14, 2010
Top Companies Feraheme Date: Jan 08, 2010 3SBio's new manufacturing facility in Shenyang to produce
Company 1 Study: HX575 is therapeutically equivalent to comparator EPIAO and TPIAO Date: Nov 13, 2009
epoetin alpha Date: Nov 01, 2010
Company 2

Company 3 Commercialization & Lobbying General News

Top Sections Intas to focus on developing biosimilars for US, EU Date: HHS Budget plan may enable FDA to provide regulatory
Monoclonal Jan 14, 2010 pathways for biosimilars Date: Jan 17, 2010
Antibodies
Biocon signs MOU with BiotechCorp to explore EGA outlines “Vision 2015” plan for generics and
GCSF
collaboration Date: Jan 14, 2010 biosimilars in Europe Date: Jan 14, 2010
EPO Teva among final three bidders for ratiopharm Date: Jan Generics would offer USD 5 billion for shorter exclusivity
19, 2010 period Date: Jan 11, 2010
Biosimilar
Events

www.indegene.com
18
CONFIDENTIAL & PROPRIETARY
 Brand Planning:
Strategic projects with broad business objectives, involving multiple stakeholders
Sample
Objective
To help the client in developing a brand plan for their asset by developing a detailed assessment of TA and competitive landscape supplemented by additional analysis including customer
behaviors, buying process, market access and pricing
Crisp breakdown of tumor types showing a
comparative assessment and risk-factors at the
beginning of the slide

Patient pool break-down as per lines of

treatment across geography

CONFIDENTIAL & PROPRIETARY

19
 Brand Planning: Snapshots
Sample
• Trial maps with trial protocol details
• Can be provided in spreadsheets also
• Value added analysis includes
probability of regulatory success and
end-date estimation

• Assessments based on possible

prospective scenarios
• Typically followed up with a quantitative
market sizing of each scenarios

CONFIDENTIAL & PROPRIETARY

20
 Commercial Assessments and Market Sizing
Triangulating quantitative data from multiple sources to arrive at commercial assessments and Insights

Objective Sample

To assess the future commercial opportunities/attractiveness of the lymphoma market. The major focus is on Non-Hodgkin Lymphoma subtypes such as follicular lymphoma (FL), diffuse
large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). The broader business question was to determine whether to pursue further research
in this area and to justify the same.
Evolving Epidemiology in each country followed by
split based on treatable and treated patient pool

CONFIDENTIAL & PROPRIETARY

21
 Commercial Assessments and Market Sizing: Snapshots
Sample

Across line split of sales by drug class-

current as well as future

Across country prospective market size

and leading drugs

CONFIDENTIAL & PROPRIETARY

22
 Clinical Trials, Pipeline Assessments

• Multi-parameter and protocol assessments of clinical studies

• Presentations as trial maps, graphic details or dynamic spreadsheets.
• Online tools for clinical trial analytics and trial modeler
• Supplementing probability of success, unmet need assessments and scenario planning

“This map is very impressive! I especially like how easy it is to use (user friendly), and how
the updated version includes the additional compounds and press releases. Very nice job.”

CONFIDENTIAL & PROPRIETARY

23
 Exploratory assessments- Oncolytics
Assessment of niche areas to determine opportunities and lucrativeness

Objective Sample

Exploratory assessment of Oncolytics as a potential/novel approach to cancer therapeutics. The types of oncolytics platform and any successes of clinical PoC.
The assessment gauged the current landscape of Oncolytics- their usage in multiple tumor types and eventually their lucrativeness as a potential in-licensing candidates

CONFIDENTIAL & PROPRIETARY

24
 In-licensing Dashboards
Objective Sample

To develop a dashboard which will help identify and prioritize the pipeline oncolytic platform candidates and also help rank them based on weightages given to
various parameters to aid in the candidate selection for acquisition/in-licensing

Methodology and assumptions

developed by Indegene Excel dashboard on oncolytics
candidate ranked based on
lucurativeness for in-licensing

CONFIDENTIAL & PROPRIETARY

25
 Epidemiology, Patient Flow
• Team of Epidemiologist well versed with various aspects of epidemiology assessments
• Detailed Epidemiology segregated across lines of therapies, severity, geography and stages of patient journey
• Qualitative and Quantitative patient flow; expertise in multiple TAs.
• Supplementing Market sizing, forecasting, HEOR assignments

“In general, I am very happy with the ….. Report”

“Thanks a lot for this team ! Looks much better”

CONFIDENTIAL & PROPRIETARY

26
 Web Platform Output Snapshot (1/2) • News updated on a daily basis
• Shortcuts and ready reference for
Platform homepage
therapy/product updates
Sample
Latest Scientific monitor: Key opinion leader database:
updated Clinical trials, journals, and • Individuals: updated monthly
news conferences • Cancer groups: updated monthly

Patient opinion report

Therapy landscape:
• Statistics: updated quarterly or
based on availability of information
• Staging: dynamically linked to
P Easy shortcuts to other sections
search for news • Guidelines: updated quarterly

Market monitor:
monthly update report
for approved products,
pipeline products,
targets, and company

CONFIDENTIAL & PROPRIETARY

27
 Web Platform Output Snapshot (2/2)
Weekly alert
Sample

P
Click here to go to Indicates level of
detailed news relevance to client’s
requirements

Click here to go directly to

Web site link

CONFIDENTIAL & PROPRIETARY

28
 Conference Coverage
• Live, virtual and offsite conference coverage service
• Service includes- Pre-conference abstracts hand-book preparation and prioritization, live conference attending, daily debriefing, OL
engagement, post-conference report and summaries
• Covered major conferences in Oncology and Cardiology space- US and EU

“I am very happy with the excellent ASH update you delivered within the discussed
timeline. Thanks for a job well done.”

CONFIDENTIAL & PROPRIETARY

29
 KOL Research- Identification, Profiling and Mapping
Objective Sample

To identify and profile the opinion leaders in a therapy area. The detailed profile covered their involvement in clinical trials, presentations of studies, affiliation to
a corporate unit and publications along with their contact details. As a next step, Indegene also ranked by assigning certain pre-agreed weightings and scores to
each of their activity.

CONFIDENTIAL & PROPRIETARY

30
 Analytics: Dash-boarding
Patient Based & Performance Dashboards Delivered on a Regular Basis

Objective Sample

To develop insightful, crisp, and non-CI centric dashboard, based on Ipsos synovate data in a pre-specified template. Such dashboards are being developed for as much as 8 tumor
types and updated and delivered every quarter since 2013

CONFIDENTIAL & PROPRIETARY

31
 Dashboard Reports with Insights
Indegene provides option for reports and insights on various user interfaces

Share Point enabled Dashboards Web based dashboards iPad enabled dashboards

Reports and Insights

MS Excel/VBA based iPhone enabled

dashboards dashboards
CONFIDENTIAL & PROPRIETARY
32
 Thank You

Thank You!

CONFIDENTIAL &33
PROPRIETARY